Department of Endocrinology, Gaziantep University School of Medicine, Turkey.
Clin Endocrinol (Oxf). 2011 Jan;74(1):118-24. doi: 10.1111/j.1365-2265.2010.03904.x.
Recent evidence has shown that oxidative stress may play a role in the pathogenesis of autoimmune diseases, and this is an issue of considerable research interest in the field of infiltrative ophthalmopathy. Therefore, we evaluated both the relationship between Graves' ophthalmopathy (GO) and serum levels of certain indicators of oxidative stress, and the effects of methylprednisolone treatment on serum malondialdehyde (MDA) and glutathione (GSH) levels in patients with euthyroid GO.
We compared GO patients to both Graves' patients without ophthalmopathy and healthy controls. Ultimately, we assessed four subject groups. Graves' patients with ophthalmopathy (GO) were subcategorized into two groups: Group A subjects (n = 18) were given intravenous glucocorticoid and Group B patients (n = 15) were given oral glucocorticoid. Graves' patients without ophthalmopathy comprised Group C (n = 20), and healthy controls comprised Group D (n = 15). Serum levels of MDA and GSH were measured at baseline and after 4 and 24 weeks of observation via spectrophotometric methods.
We found that serum MDA levels were significantly higher in the two GO groups (Groups A and B) than in GO patients without ophthalmopathy or healthy controls. Conversely, GSH levels were significantly lower in the two GO groups than in Groups C and D. MDA and GSH levels were not different between the latter two groups. MDA levels were strongly and positively correlated with a clinical activity score (CAS). In Group A, MDA levels and the CAS were significantly lower than in Group B at 4 weeks. After 24 weeks, however, MDA levels and the CAS were similar in these two groups.
Oxidative stress appears to be involved in the pathophysiology of GO. Relative to oral dosing, the intravenous administration of a glucocorticoid seems to yield more rapid improvement in disease activity. MDA might be useful as an indicator of clinical activity.
最近的证据表明,氧化应激可能在自身免疫性疾病的发病机制中起作用,这是浸润性眼病领域相当有研究兴趣的问题。因此,我们评估了 Graves 眼病(GO)与某些氧化应激指标血清水平之间的关系,以及甲泼尼龙治疗对甲状腺功能正常的 GO 患者血清丙二醛(MDA)和谷胱甘肽(GSH)水平的影响。
我们将 GO 患者与 Graves 病无眼病患者和健康对照组进行比较。最终,我们评估了四个实验组。GO 患者分为两组:A 组(n = 18)接受静脉注射糖皮质激素,B 组(n = 15)接受口服糖皮质激素。无眼病的 Graves 病患者为 C 组(n = 20),健康对照组为 D 组(n = 15)。通过分光光度法在基线以及观察 4 周和 24 周后测量血清 MDA 和 GSH 水平。
我们发现,两组 GO 患者(A 组和 B 组)的血清 MDA 水平明显高于无眼病的 GO 患者或健康对照组。相反,两组 GO 患者的 GSH 水平明显低于 C 组和 D 组。后两组之间的 MDA 和 GSH 水平没有差异。MDA 水平与临床活动评分(CAS)呈强烈正相关。在 A 组,4 周时 MDA 水平和 CAS 明显低于 B 组。然而,24 周后,这两组的 MDA 水平和 CAS 相似。
氧化应激似乎参与了 GO 的病理生理学。与口服给药相比,静脉内给予糖皮质激素似乎能更快地改善疾病活动。MDA 可能是评估临床活动的有用指标。